Browse > Article

Immunohistochemical Study of C-erbB-2 and VEGF Expression in Non-Small Cell Lung Cancer  

Shin, Jong Wook (Department of Internal Medicine, College of Medicine, Chung-Ang University)
Ha, Kyung Won (Department of Pathology, College of Medicine, Chung-Ang University)
Choi, Jae Cheol (Department of Internal Medicine, College of Medicine, Chung-Ang University)
Kim, Jae Yeol (Department of Internal Medicine, College of Medicine, Chung-Ang University)
Park, In Whon (Department of Internal Medicine, College of Medicine, Chung-Ang University)
Choi, Byoung Whui (Department of Internal Medicine, College of Medicine, Chung-Ang University)
Yoo, Jae Hyung (Department of Pathology, College of Medicine, Chung-Ang University)
Publication Information
Tuberculosis and Respiratory Diseases / v.62, no.1, 2007 , pp. 43-50 More about this Journal
Abstract
Background: Mutated or deregulated expression of C-erbB-2 causes this gene to function as a potent oncogene. Vascular endothelial growth factor (VEGF) is a crucial angiogenic molecule in lung cancer. Both C-erbB-2 and VEGF can promote growth, proliferation and metastasis in non-small cell lung cancer (NSCLC). The purpose of this study was to investigate evaluate the relationship between the expressions of the C-erbB-2 and VEGF genes using immunohistochemistry. Materials and Methods: Ninety-five patients with NSCLC were involved (60 squamous cell carcinoma and 35 adenocarcinoma). The formalin-fixed paraffin embedded specimens were immunohistochemically stained for C-erbB-2 and VEGF using the avidin-biotin complex method. Results: Positive C-erbB-2 expression was observed more often in adenocarcinomas than squamous cell carcinomas (p<0.05). Although the immunohistochemical expressions of C-erbB-2 and VEGF in non-small-cell lung cancer showed increased tendencies at an advanced stage, the correlation between early and advanced cancers was insignificant. In adenocarcinomas, the expressions of VEGF and C-erbB-2 were significantly (p<0.05). Conclusion: The overexpression fo C-erbB-2 was significantly higher in adenocarcinomas than squamous cell carcinomas, and correlated with the expression of VEGF in adenocarcinomas of the lungs.
Keywords
C-erbB-2; VEGF; Non-small-cell lung cancer;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Henengstler JG, Lange J, Kett A, Dornhofer N, Meinert R, Arand M, et al. Contribution of c-erbB-2 and topoisomerase II alpha to chemoresistance in ovarian cancer. Cancer Res 1999;59:3206-14
2 Hansen HH. An update on management for lung cancer: Acta Oncologica Lecture-Vasteras 21 March 2002. Acta Oncol 2002;41:500-6   DOI   ScienceOn
3 Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and this receptor, KDR, correlates with vascularity, metastasis and proliferation of humancancer. Cancer Res 1995;55:3964-8
4 Korrapati V, Gaffney M, Larsson LG, Nunno LD, Riggs M, Beissner RS, et al. Effects of HER-2/neu expression on survival in non small cell lung cancer. Clin Lung Cancer 2001;2:216-9   DOI   ScienceOn
5 Itakura Y, Sasano H, Shiaga C. Furukawa Y, Shiga K, Mori S, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma: an immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994;74: 795-804   DOI   ScienceOn
6 Lohrisch C, Piccart M. An overview of HER-2. Semin Oncol 2001;28(6 Suppl):3-11
7 Brabernder J, Danenberg KD, Metzger R, Schneider PM, Park J, Salinga D, et al. Epidermal growth factor receptor and HER-2-neu mRNA expression in non-small-cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-5
8 Folkman J, Watson K,Ingiber D, Hanahan D. Induction of angiogenesis during the transitionfrom hyperplasia to neoplasia.1989;339:58-61   DOI   ScienceOn
9 Ross JS, Fletcher JA. HER-2/neu(c-erbB-2) gene and protein in breast cancer. Am J Clin Pathol 1999;112 (Suppl 1):S53-67
10 Allred DC, Swanson PE. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 2000;113:171-5   DOI   ScienceOn
11 Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, et al. Epidermal growth factor receptor andmRNA expression in non small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-5
12 Yano T, Tanikawa S, Fujie T, Masutani M, Horie T. Vascular endothelial growth factor expression and neovascularization in non-small cell lung cancer. Eur J Cancer 2000;36:601-9   DOI   ScienceOn
13 Weidman N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Drug Dev Res 1996;25: 249-65
14 Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Shinitt SJ. Specificity of Hercep Test in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-7   DOI
15 Shak S. Overview of the trastuzumab(Herceptin$^{\circledR}$) anti HER-2 monoclonal antibody clinical program in HER-2 overexpressing metastatic breast cancer. Semin Oncol 1999;26:71-7
16 Brattstrom D, Wester K, Bergqvist M, Hesselius P, Malmstrom PU, Nordgren H, et al. HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer. Acta Oncol 2004;43:80-6   DOI   ScienceOn
17 Hirsch FR, Varcella-Garcia M, Franklin WA, Veve R, Cehn L, Helfrich B, et al. Evaluation of HER-2/neu gene amplification and protein expression in nonsmall- cell lung carcinomas. Br J Cancer 2002;86: 1449-56   DOI   ScienceOn
18 Kerbel RS, Klement G, Prichard KI, Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002;13:12-5   DOI   ScienceOn
19 Wester K, Sjostrom A, Torre M, Carlsson J, Malmstrom PU. HER-2: a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 2002;41:282-8   DOI   ScienceOn
20 Nahta R, Trent S, Yang C, Schmidt EV. Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer. Cancer Res 2003; 63:3626-31
21 Solbach C, Roller M, Budischewski K, Loibl S, Nicoletti M, Stegmueller M, et al. EGFR and Her2/ neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapy. J Cancer Res Clin Oncol 2003;129: 250-1
22 Newby JC, A'Hern RP, Leek RD, Smith IX, Harris AL, Dowsett M. Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-bindingand clinical relevance in breast cancer. Br J Cancer 1995;71: 1237-42   DOI   ScienceOn
23 Riou G, Mathieu MC, Barrois M, Le Bihan ML, Ahomadegbe JC, Benard J, et al. C-erbB-2(HER-2/ neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer 2001;95:266-70   DOI   ScienceOn
24 Bunn PA Jr, Helfrich B, Soriano A, Franklin WA, Varella-Garcia M, Hirsch F, et al. Expression of HER-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and relationship to in vitro cytotoxicity by trastuzumab and cytotherapeutic. Clin Cancer Res 2001;7:3239-50
25 Izumi Y, Xu L, Tomaso E, Fukumura D, Jain RK. Tumour biology Herceptin${\circledR}$ acts as an anti-angiogenetic cocktail. Nature 2002;416:279-80
26 Hsieh CC, Chow KC, Fahn HJ, Tsai CM, Liu WY, Huang MH, et al. Prognostic significance of HER-2/ neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg 1998;66:1159-64   DOI   ScienceOn
27 Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 199917: 1974-82   DOI
28 Beenken SW, Gizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, et al. Molecular biomarkers for breast cancer prognosis: coexpression of C-erbB-2 of p53. Ann Surg 2001233:630-8   DOI   ScienceOn
29 David L, Serruca R, Nesland JM, Soares P, Sansonetty F, Holm R, et al. C-erb-B2 expression in primary gastric carcinoma and their metastases. Mod Pathol 1992;5:384-90